RSSDI Repository, Complications of Diabetes Demonstration RSSDI Repository, Complications of Diabetes Demonstration

Have a Question?

If you have any question you can ask below or enter what you are looking for!

  • Home/
  • Article /
  • Effect of a Dual PPAR alpha/gamma agonist on Insulin Sensitivity in Patients of Type 2 Diabetes with Hypertriglyceridemia- Randomized double-blind placebo-controlled trial.

Effect of a Dual PPAR alpha/gamma agonist on Insulin Sensitivity in Patients of Type 2 Diabetes with Hypertriglyceridemia- Randomized double-blind placebo-controlled trial.

Add to Collection
2019 Dec 12 RCTs Fist_Author_Year_PM

Full Author : ['Jain, Nimisha', 'Bhansali, Shobhit', 'Kurpad, Anura V', 'Hawkins, Meredith', 'Sharma, Akhilesh', 'Kaur, Sandeep', 'Rastogi, Ashu', 'Bhansali, Anil']
Journal Title : Scientific reports
Chapter : Section3
Journal Year : 2019
Cited by : Not Available

Saroglitazar is a dual PPAR-alpha/gamma agonist approved for the treatment of diabetic dyslipidemia. In addition to reduction in atherogenic lipids, it may also contribute to improvement in insulin sensitivity through PPAR-alpha/gamma agonism, which remai.....

Keywords : ["hypertriglyceridemia randomize doubleblind placebocontrolle trial", "dual ppar alphagamma agonist", "type diabetes", "insulin sensitivity", "patient", "effect"]